ASCO GU 2024

BRCAAway - practice changing or hypothesis generating data?

Combination vs. monotherapy - a great new option for high-risk patients

Cabo + IO: Interesting but not practice changing?!

Is "more" always better?

Dose de-escalation in different ways

Stockholm3 validated in multiethnic cohort

Olaparib + Arbiraterone better compared to either alone

Therapy Intensification Still Neglected in mHSPC

Combination NHT + PARP makes sense

Gleason 3+3 - cancer or not?

Localized PCa - news for radiotherapy and biochemical recurrence

Evaluating the recombination-repair mutations in patients with mCRPC

BRCAaway - PARP combination study

Combination of cabozantinib & checkpoint inhibitor

Quality of life under intensive therapy

Relugolix combined with androgen signaling in real word experience

What about the clinical benefit?

Further testing before olaparib combination

Higher radiation is effective in high-risk PCA

Insights and news for mCRPC

Enzalutamide therapy as option for biochemical recurrence

Long-term dose escalation - Therapy in high-risk prostate cancers

Still a difficult time for androgenic inhibitors in mCRPC

Salvage radiation with anti-androgen superior to radiation alone

First positive study of IO therapy in mCRPC

Cognitive function in ART treatment

BRCAAway - PARP hämmare, abiraterone eller i kombination

Gleason 3+3 ska vi kalla de cancer eller inte?

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

Kognitiv påverkan av abirateron och enzalutamid?

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

Kombination av cabozantinib och immunterapi

Advances in (neo)-adjuvant treatment in urothelial cancer

New standard of care, but still open questions!

The emerging field of biomarkers in bladder cancer

ADC + ICI: new data for platinum-refractory bladder cancaer patients

ASCO GU24 - Highlights in Bladder cancer

Pembrolizumab adjuvant in bladder cancer

MIBC: adjuvant PD1 - all set?!

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

HER2 and bladder cancer

Update M1 urothelial cancer

EV + Pembro new first-line standard in localized metastatic bladder cancer

Highlights in bladder cancer at ASCO GU24

Biomarker update

Perioperative adjuvant therapy in urothelial cancer

Another success for an ICI?

EV as standard in 3rd line mUC

Update on EV-302

Terapia adyuvante perioperatoria en el cáncer de vejiga

Encore un succès pour une ICI ?

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

Novedades sobre EV-302

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

No surprise with the QoL data

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

Subcutaneous vs. intravenous application: ready for everyday clinics?

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

Long-term outcome

ASCO GU24 - Highlights in renal cell carcinoma

Highlights in kidney cancer at ASCO GU24

Long-Term Data on NIVO+IPI in aRCC

Better QoL with Belzutifan

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Belzutifan: Updates on QoL

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Overall survival benefit - Pembro after surgery

Tumorburden and outcome

Perioperative treatment in renal cell carcinoma - did we close the circle?

Durable effects of Ipi-Nivo

Practice changing adjuvant therapy?!

Long-term follow-up of first-line trials

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?